Skip to main content

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  266.03
+15.34 (6.12%)
AAPL  349.51
+17.61 (5.31%)
AMD  488.78
+4.88 (1.01%)
BAC  51.63
+1.97 (3.97%)
GOOG  287.30
+9.03 (3.25%)
META  630.00
+8.97 (1.44%)
MSFT  555.80
+34.81 (6.68%)
NVDA  200.13
-6.56 (-3.17%)
ORCL  123.73
-2.46 (-1.95%)
TSLA  385.19
-13.31 (-3.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.